The Coagulopathy of Acute Leukemia

References

• Rodeghiero F., Castaman G. Disseminated intravascular coagulation in acute leukemia. “Infections and Haemorrhage in Acute Leukaemia”, T. Barbui, A. Falanga, B. Minetti, S. Gorini, G. Tognoni, M. B. Donati. John Libbey Eurotext, London-Paris 1989; 45–63
   Google Scholar
• Groopman J., E Uman L. Acute promyelocytic leukemia. American Journal of Hematology 1979; 7: 395–408
   PubMed Web of Science ®Google Scholar
• Pitney W. R., Phadke K. P., Dean S. Anti-thrombin III deficiency during asparaginase therapy. Lancet 1980; 1: 493–4
   PubMed Web of Science ®Google Scholar
• Vellenga E., Mulder N. H., Nieweg H. O. Anti-thrombin III deficiency during asparaginase therapy. Lancet 1980; 1: 649–50
   PubMed Web of Science ®Google Scholar
• Conrad J., Cazenave B., Maury J., Horellou M. H., Samama M. L-asparaginase, antithrombin III and thrombosis. Lancet 1980; 1: 1091
   PubMed Web of Science ®Google Scholar
• Priest J. R., Ramsey M. R., Latchan R. E., Krivit W. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980; 46: 1548–54
   PubMed Web of Science ®Google Scholar
• Steinherz P. G., Miller P. L., Ghavimi F., Allen J. C., Miller D. R. Dural sinus thrombosis in children with acute lymphoblastic leukemia. Journal of American Medical Association 1981; 246: 2837–9
   Web of Science ®Google Scholar
• Barbui T., Rodeghiero Meli F. S., Dini E. Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy. Acta Haematologica 1983; 69: 188–91
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Castaman G., Dini E. Fibrino-peptide A changes during remission induction treatment with L-Asparaginase in acute lymphoblastic leukemia: evidence for activation of blood coagulation. Thrombosis Research 1990; 57: 31–8
   PubMed Web of Science ®Google Scholar
• Castaman G., Rodeghiero F., Dini E. Thrombotic complications during L-asparaginase treatment for acute lymphocytic leukemia. Haematologica 1990; 75: 567–9
   PubMedGoogle Scholar
• Barbui T., Finazzi Vigand G. S., Mannucci P. M. L-asparaginase lowers protein C antigen. Thrombosis and Haemostasis 1984; 52: 216
   PubMed Web of Science ®Google Scholar
• Gugliotta L., D'Angelo A., Mattioli Belmonte M., Vigand D'Angelo S., Colombo G., Catani L., Gianni L., Lauria F., Tura S. Hypercoagulability during L-asparaginase treatment: the effect of antithrombin III supplementation in vivo. British Journal of Haematology 1990; 75: 465–9
   Web of Science ®Google Scholar
• Gouault-Heilmann M., Chardon E., Sultan C., Josso F. The nrocoaeulant factor of leukaemic cells: demon-stration of immunologic cross-reactivity with human brain tissue factor. British Journal of Haematology 1975; 30: 151–8
   PubMed Web of Science ®Google Scholar
• Gordon S. G., Cross B. A. A factor X activating cysteine protease from malignant tissue. Journal of Clinical Investigation 1981; 67: 1655–61
   Web of Science ®Google Scholar
• Gordon S. G., Hashiba U., Poole M. A., Cross S. B., Falanga A. A cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66: 1261–5
   PubMed Web of Science ®Google Scholar
• Ouigley H. J. Peripheral leukocyte thromboplastin in promyelocytic leukemia. Federation Proceedings 1967; 26: 648, abs
   Google Scholar
• Gralnick H. R., Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. British Journal of Haematology 1973; 24: 89–99
   PubMed Web of Science ®Google Scholar
• Sakuragawa N., Takahashi K., Hoshiyama M., Jimbo C., Matsuoka M., Onishy J. Pathologic cells as pro-coagulant substance of disseminated intravascular coagulation syndrome in acute promyelocytic leukemia. Thrombosis Research 1976; 8: 263–73
   PubMed Web of Science ®Google Scholar
• Wada H., Nagano T., Tomeoku M., Kuto M., Karitani Y., Deguchi K., Shirakawa S. Coagulant and fibrinolytic activities in the leukemic cells lysates. Thrombosis Research 1982; 30: 315–22
   Web of Science ®Google Scholar
• Guarini A., Gugliotta L., Timoncini C., Chetti L., Catani L., Russo D., Tura S. Procoagulant cellular activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scandinavian Journal of Haematology 1985; 34: 152–6
   PubMedGoogle Scholar
• Guarini A., Gugliotta L., Catani L., Chetti L., Macchi S., Tura S. Procoagulant cellular activity (PCA) in the classification of acute leukemia. Thrombosis Research 1987; 45: 545–52
   PubMed Web of Science ®Google Scholar
• Lyberg T., Ivhed I., Prydz H., Nilsson K. Thromboplastin as a marker of monocyte differentiation. British Journal of Haematology 1983; 53: 327–35
   PubMed Web of Science ®Google Scholar
• Pogliani E., Gambacorti-Passerini C., Cofrancesco E., Donati M. B., Semeraro N. Impaired generation of procoagulant activity in leukaemic monoblasts. British Journal of Haematology 1986; 62: 197–9
   PubMed Web of Science ®Google Scholar
• Guarini A., Gugliotta L., Valvassori L., Bagnara G. P., Timoncini C., Motta M. R., Chetti L., Catani L., Russo D., Tura S. Human myeloid precursor cells do not possess or produce procoagulant activity (PCA). Experimental Hematology 1986; 14: 72–4
   PubMed Web of Science ®Google Scholar
• Falanga A., Alessio M. G., Donati M. B., Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870–5
   PubMed Web of Science ®Google Scholar
• Alessio M. G., Falanga A., Consonni R., Bassan R., Minetti B., Donati M. B., Barbui T. Cancer procoagulant in acute lymphoblastic leukemia. European Journal of Haematology 1990; 45: 78–81
   PubMed Web of Science ®Google Scholar
• Donati M. B., Falanga A., Consonni R., Alessio M. G., Bassan R., Buelli M., Bonn L., Catani L., Pogliani E., Gugliotta L., Masera G., Barbui T. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thombosis and Haemostasis 1990; 64: 11–6
   PubMed Web of Science ®Google Scholar
• Gordon S., Marlar R., Madden R., Falanga A. Inactivation of the protein C system by cancer procoagulant. Thrombosis and Haemostasis 1989; 62: 40, abs. 87
   Web of Science ®Google Scholar
• Wijermans P. W., Rebel V. I., Ossenkoppele, Huij-Gens G. J. P. C., Langenhuijsen M. M. A.C. Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: reversal of the bleeding disorder by cell differentiation. Blood 1989; 73: 800–5
   PubMed Web of Science ®Google Scholar
• Wilson E. L., Jacobs P., Dowdle E. B. The secretion of plasminogen activators by human myeloid leukemic cells in vitro. Blood 1983; 61: 568–74
   PubMed Web of Science ®Google Scholar
• Bennett B., Booth N. A., Croll A., Dawson A. A. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. British Journal of Haematology 1989; 71: 511–7
   PubMed Web of Science ®Google Scholar
• Schmidt W., Egbring R., Haveman K. Effect of elastase-like and of chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. Thrombosis Research 1974; 6: 315–21
   Web of Science ®Google Scholar
• Dewald B., Rindler-Ludwig R., Bretz U., Baggiolini M. Subcellular localization and heterogeneity of neutral proteases in neutrophilic polymorphonuclear leukocytes. Journal of Experimental Medicine 1975; 141: 709–23
   PubMed Web of Science ®Google Scholar
• Egbring R., Schmidt W., Fuchs G., Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977; 49: 219–31
   PubMed Web of Science ®Google Scholar
• Myers T. J., Rickles F. R., Barb C., Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood 1981; 57: 518/25
   Web of Science ®Google Scholar
• Bauer K. A., Rosenberg R. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64: 791–6
   PubMed Web of Science ®Google Scholar
• Gugliotta L., Viganò S., D'Angelo A., Guarini A., Tura S., Mannucci P. M. High fibrinopeptide A (FPA) levels in acute non-lymphocytic leukemia are reduced by heparin administration. Thrombosis and Haemostasis 1984; 52: 301–4
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Castaman G., Soffiati G., Quaglio R., Castronovo S., Cortesi S., Dini E. Clinical significance of fibrinopeptide A in acute lymphocytic and non-lymphocytic leukemia. Blut 1989; 59: 177–83
   PubMedGoogle Scholar
• Scharf R. E., Schneider W. Relationship of thrombin generation to peripheral blast cell count in patients with acute myeloblasts leukemia (AML). European Journal of Haematology 1990; 44: 273–6
   PubMed Web of Science ®Google Scholar
• Yoda Y., Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patient with malignant disease. Thrombosis and Haemostasis 1981; 46: 706–9
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Barbui T., Battista R., Chises T., Rigoni G., Dini E. Molecular subunits and transmadidase activity of factor XIII during disseminated intravascular coagulation in acute leukemia. Thrombosis and Haemostasis 1980; 43: 6–9
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Morbin M., Barbui T. Subunit A of factor XIII regulates subunit B plasma concentration. Thrombosis and Haemostasis 1981; 46: 621–2
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Barbui Dal T., Belin Peruffo A., Dini E. Defective fibrin cross-linking in acute leukemia. Thrombosis and Haemostasis 1984; 52: 343–6
   PubMed Web of Science ®Google Scholar
• Ballerini G., Guerra S., Rodeghiero F., Castaman G. A contribution to the pathology of acquired plasma factor XIII deficiency. Seminars in Thrombosis and Hemostasis 1985; 11: 357–61
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Mannucci P. M., Viganb S., Barbui T., Gugliotta L., Cortellaro M., Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63: 965–9
   PubMed Web of Science ®Google Scholar
• Muller-Berghaus G., Niepoth M., Rabens Alles B., Rump E., Murano G. Normal antithrombin III activity and concentration in experimental disseminated intravascular coagulation. Scandinavian Journal of Clinical and Laboratory Investigation 1985; 45(suppl. 1)107–13
   Google Scholar
• Avvisati G., ten Cate J. W., Lamping R., Petti M. C., Mandelli F. Acquired α-2-antiplasmin deficiency in acute promylelocytic leukemia. British Journal of Haematology 1988; 70: 43–8
   PubMed Web of Science ®Google Scholar
• Schwartz B. S., Williams E. C., Conlan M. G., Mosher D. F. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alfa-2-plasmin inhibitor deficiency. Annals of Internal Medicine 1986; 105: 873–7
   PubMed Web of Science ®Google Scholar
• Guarini A., Mussoni L., Gugliotta L., Chetti L., Niewiarowski T., Catani L., Macchi S., Donati M. B., Tura S. Depressed fibrinolysis in patients with acute leukaemia. British Journal of Haematology 1987; 66: 323–6
   PubMed Web of Science ®Google Scholar
• Champlin R., Gale R. P. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551–62
   PubMed Web of Science ®Google Scholar
• Bernard J., Weil M., Boiron M., Jacquillat C, Flandrin G., Gemon M. F. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973; 41: 489–96
   PubMed Web of Science ®Google Scholar
• Hoyle C. F., Swirsky D. M., Freedman L., Hayhoe F. G.J. Beneficial effect of heparin in the management of patients with APL. British Journal of Haematology 1988; 68: 283–9
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Walters R. S., Estey E. H., McCredie K. B., Smith T., Dalton W., Cork A., Tru-Jillo J. M., Freireich E. J. Acute promyelocytic leukemia. M. D. Anderson Hospital experience. American Journal of Medicine 1986; 80: 789–97
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Avvisati G., Castaman G., Barbui T., Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112–7
   PubMed Web of Science ®Google Scholar
• Sanz M., Jargue I., Martin G., Lorenzo I., Martinez J., Rafecas J., Pastor E., Sayas M. J., Sanz G., Gomis F. Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988; 61: 7–13
   PubMed Web of Science ®Google Scholar
• Marty M., Ganem G., Fischer J., Flandrin G., Berger R., Schaison G., Degos L., Boiron M. Leucemie agigue promyelocytaire: etude retrospective de 119 malades traitee par daunorubicine. Nouvelle Revue Francaise d'Hematologie 1984; 26: 371–8
   PubMedGoogle Scholar
• Baker W., Bang N. U., Nachman R. L., Raafat R., Horowitz H. I. Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin. Annals of Internal Medicine 1964; 61: 116–23
   PubMed Web of Science ®Google Scholar
• Gralnick H. R., Bagley J., Abreli E. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. American Journal of Medicine 1972; 52: 167–74
   PubMed Web of Science ®Google Scholar
• Goldberg M. A., Ginsburg D., Mayer R. J., Stone M. R., Maguire M., Rosenthal D. S., Antin J. H. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood 1987; 69: 187–91
   PubMed Web of Science ®Google Scholar
• Petti M. C., Avvisati G., Amadori S., Baccarani M., Guarini A. R., Papa G., Rosti G. A., Tura S., Mandelli F. Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica 1987; 72: 151–5
   PubMed Web of Science ®Google Scholar
• Wintrobe M. M., Lee G. R., Boggs D. R., Bithell T. C., Roerstor J., Athons J. W., Lukens J. N. Clinical Hematology. Lea and Febiger, Philadelphia 1981
   Google Scholar
• Williams W. J., Beutler E., Erslev A. J., Lichtman M. A. Hematology. McGraw-Hill, New York 1991
   Google Scholar
• Ruggero D., Baccarani M., Guarini A. Acute promyelocytic leukemia: results of therapy and analysis of 13 cases. Acta Haematologica 1977; 58: 108–19
   PubMed Web of Science ®Google Scholar
• Drapkin R. L., Gee T. S., Dowling M. D., Arlin Z., McKenzie S., Kempin S., Clarkson B. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484–90
   PubMed Web of Science ®Google Scholar
• Collins A. J., Bloomfield C. D., Peterson B. A., McKenna R. W., Edson J. R. Acute promyelocytic leukemia: management of the coagulopathy during daunorubicin-pred-nisone remission induction. Archives of Internal Medicine 1978; 138: 1677–80
   PubMed Web of Science ®Google Scholar
• Daly P. A., Schiffer C. A., Wiernik P. H. Acute promyelocytic leukemia: clinical management of 15 patients. American Journal of Haematology 1980; 8: 347–59
   PubMed Web of Science ®Google Scholar
• Cordonnier C., Vernant J. P., Brun B., Gouault-Heilmann M., Kuentz M., Bierling P., Farcet J. P., Rodet M., Due-Dari N, Imbert M., Jouault H., Mannoni P., Reyes F., Dreyfus B., Rochant H. Acute promyelocyte leukemia in 57 previously untreated patients. Cancer 1985; 55: 18–25
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T. S., Reich L. M., Kempin S. J., Naval A. N., Clarkson B. D. Acute promyelocytic leukemia: treatments results during a decade at Memorial Hospital. Blood 1989; 73: 1116–9
   PubMed Web of Science ®Google Scholar
• Avvisati G., ten Cate J. W., Buller H. R., Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989; 2: 122–4
   PubMed Web of Science ®Google Scholar